000856060 001__ 856060
000856060 005__ 20210129235230.0
000856060 0247_ $$2doi$$a10.1007/s11910-018-0898-3
000856060 0247_ $$2ISSN$$a1528-4042
000856060 0247_ $$2ISSN$$a1534-6293
000856060 0247_ $$2pmid$$apmid:30293094
000856060 0247_ $$2WOS$$aWOS:000446537500003
000856060 0247_ $$2altmetric$$aaltmetric:49470336
000856060 037__ $$aFZJ-2018-05725
000856060 082__ $$a610
000856060 1001_ $$0P:(DE-HGF)0$$aHammes, Jochen$$b0$$eCorresponding author
000856060 245__ $$aThe Role of Tau Imaging in Parkinsonian Disorders
000856060 260__ $$aPhiladelphia, Pa.$$bCurrent Science Inc.$$c2018
000856060 3367_ $$2DRIVER$$aarticle
000856060 3367_ $$2DataCite$$aOutput Types/Journal article
000856060 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1539094296_10156
000856060 3367_ $$2BibTeX$$aARTICLE
000856060 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000856060 3367_ $$00$$2EndNote$$aJournal Article
000856060 520__ $$aPurpose of ReviewDifferential diagnosis of atypical Parkinson syndromes (APS) is difficult as clinical presentations may vary and as there is a strong overlap between disease entities. Aggregations of misfolded and hyperphosphorylated tau proteins are the common denominator of many of these diseases.Recent FindingsSeveral tau targeting positron emission tomography (PET) tracers have been evaluated as possible biomarkers in APS in the recent years. For Parkinson’s disease, dementia with Lewy bodies, progressive supranuclear palsy, and corticobasal degeneration, promising results have been reported with regard to the ability to detect the presence of disease and to discriminate patients from controls. However, the discussion about the specificity of the first-generation radiotracers and their value in the clinical context is ongoing.SummaryA combined interpretation of signal strength and distribution pattern in PET scans with first- and second-generation tracers may be helpful in clinical diagnosis and follow-up of patients with APS
000856060 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000856060 588__ $$aDataset connected to CrossRef
000856060 7001_ $$0P:(DE-HGF)0$$aDrzezga, Alexander$$b1
000856060 7001_ $$0P:(DE-Juel1)169110$$avan Eimeren, Thilo$$b2
000856060 773__ $$0PERI:(DE-600)2094171-7$$a10.1007/s11910-018-0898-3$$gVol. 18, no. 12, p. 86$$n12$$p86$$tCurrent neurology and neuroscience reports$$v18$$x1534-6293$$y2018
000856060 8564_ $$uhttps://juser.fz-juelich.de/record/856060/files/Hammes2018_Article_TheRoleOfTauImagingInParkinson.pdf$$yRestricted
000856060 8564_ $$uhttps://juser.fz-juelich.de/record/856060/files/Hammes2018_Article_TheRoleOfTauImagingInParkinson.pdf?subformat=pdfa$$xpdfa$$yRestricted
000856060 909CO $$ooai:juser.fz-juelich.de:856060$$pVDB
000856060 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)169110$$aForschungszentrum Jülich$$b2$$kFZJ
000856060 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000856060 9141_ $$y2018
000856060 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCURR NEUROL NEUROSCI : 2017
000856060 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000856060 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000856060 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000856060 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000856060 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000856060 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000856060 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000856060 920__ $$lyes
000856060 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000856060 980__ $$ajournal
000856060 980__ $$aVDB
000856060 980__ $$aI:(DE-Juel1)INM-3-20090406
000856060 980__ $$aUNRESTRICTED